You are about to leave the Clinical Value website now.

Cancel

Performance evaluation of the Elecsys PIVKA-II and Elecsys AFP assays for hepatocellular carcinoma diagnosis

Quick Summary

Prothrombin induced by vitamin K absence-II (PIVKA-II) is a serum biomarker linked to hepatocellular carcinoma (HCC), showing superiority to alpha-fetoprotein (AFP) for early disease detection. This study assesses the clinical and analytical performance of the Elecsys® PIVKA-II immunoassay in diagnosing HCC and evaluate PIVKA-II’s technical performance.

You May Also Like

9 December 2022

Elecsys PIVKA-II and Elecsys AFP assays demonstrate good clinical performance for hepatocellular carcinoma (HCC) diagnosis across different disease stages and aetiologies

This study evaluates the clinical performance of the new Elecsys PIVKA-II immunoassay and the previously launched Elecsys AFP assay (Roche Diagnostics) to aid in the diagnosis of HCC, according to…

Read More
9 December 2022

Analytical performance and method comparison of the Elecsys PIVKA-II immunoassay as an aid in diagnosis of hepatocellular carcinoma (HCC)

This study evaluates the analytical performance of the Elecsys PIVKA-II immunoassay to aid in HCC diagnosis, establish method-specific reference ranges in healthy individuals, and perform a method comparison versus commercially…

Read More
9 December 2022

Clinical evaluation of Elecsys PIVKA-II for patients with advanced hepatocellular carcinoma

Prothrombin induced by vitamin K absence-II (PIVKA-II) was reported as a diagnosis and prognosis marker for hepatocellular carcinoma (HCC). This prospective study aims to comparatively verify Elecsys PIVKA-II and conventional…

Read More

SHARE

Be the first to receive updates, event opportunities, and thought leadership insights.